A Phase 1/2 interventional study of Intralesional/ Intravenous of Autologous Stem cells. in Muscular Dystrophy and Duchenne Muscular Dystrophy, sponsored by Chaitanya Hospital, Pune. Status unknown at 1 site in India. Open to participants aged 4 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-17.
Sponsored by Chaitanya Hospital, Pune · Phase 1/2, Interventional, and Treatment
This Study is single arm, single center trial to check the safety and efficacy of BMMNC (100 million per dose) for the patient with Duchenne Muscular Dystrophy,
Muscular dystrophies, or MD, are a group of inherited conditions, which means they are passed down through families. They may occur in childhood or adulthood. There are many different types of muscular dystrophy. They include:
Duchenne muscular dystrophy is a form of muscular dystrophy that worsens quickly. Other muscular dystrophy (including Becker's muscular dystrophy) get worse much more slowly.
Duchenne muscular dystrophy is caused by a defective gene for dystrophin (a protein in the muscles). However, it often occurs in people without a known family history of the condition.
Symptoms usually appear before age 6 and may appear as early as infancy. They may include:
Fatigue
Learning difficulties (the IQ (intelligence quotient )can be below 75)
Intellectual disability (possible, but does not get worse over time)
Muscle weakness
Begins in the legs and pelvis, but also occurs less severely in the arms, neck, and other areas of the body
Difficulty with motor skills (running, hopping, jumping)
Frequent falls
Trouble getting up from a lying position or climbing stairs
Weakness quickly gets worse
Progressive difficulty walking
Ability to walk may be lost by age 12, and the child will have to use a wheelchair
Breathing difficulties and heart disease usually start by age 20
548 studies on the registry are indexed under Muscular Dystrophies; 89 are open to participants now.
This study's planned enrollment of 30 is above the median of 24 across 344 interventional studies indexed under Muscular Dystrophies.
Browse Muscular Dystrophies studies →Chaitanya Hospital, Pune is the lead sponsor of 14 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intralesional/ Intravenous of Autologous Stem cells.
Other: Intralesional/ Intravenous of Autologous Stem cells.
Intralesional/ Intravenous of Autologous MNCs per dose
Also known as: Intralesional/ Intravenous of Autologous MNCs., Intralesional/ Intravenous of Autologous MNCs
Improvement of daily living scale.
Time frame: 6 MONTH
Improvement of Muscular dystrophy specific functional Rating scale
Time frame: 6 Months
This study is status unknown, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chaitanya Hospital, Pune